The executive team at MyMD has a lengthy history of successful alliances with industry and academia. In general, the company seeks to develop compounds to successful proof of concept in human clinical trials. We are open to expressions of interest with respect to partnership at all stages of development. MyMD is uniquely positioned to leverage internal scientific and developmental expertise for the common goal of improving quality of life. Additionally, MyMD is open to in-licensing proposals that are in alignment with the company’s overall therapeutic focus in cancers, autoimmune disorders and CNS diseases.
A detailed electronic presentation of the elegant mechanism of action, extensive preclinical data, IP and IND is available to potential partnering candidates interested in acquiring global rights to MYMD-1.
We look forward to evaluating assets that have the potential to expand our pipeline or technological base for the pursuit of R&D excellence that can translate into new medicines to better affect patients’ lives.